7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Opportunistic prostate cancer (PCa) screening is a controversial topic. Magnetic resonance imaging (MRI) has proven to detect prostate cancer with a high sensitivity and specificity, leading to the idea to perform an image-guided prostate cancer (PCa) screening; Methods: We evaluated a prospectively enrolled cohort of 49 healthy men participating in a dedicated image-guided PCa screening trial employing a biparametric MRI (bpMRI) protocol consisting of T2-weighted (T2w) and diffusion weighted imaging (DWI) sequences. Datasets were analyzed both by human readers and by a fully automated artificial intelligence (AI) software using deep learning (DL). Agreement between the algorithm and the reports—serving as the ground truth—was compared on a per-case and per-lesion level using metrics of diagnostic accuracy and k statistics; Results: The DL method yielded an 87% sensitivity (33/38) and 50% specificity (5/10) with a k of 0.42. 12/28 (43%) Prostate Imaging Reporting and Data System (PI-RADS) 3, 16/22 (73%) PI-RADS 4, and 5/5 (100%) PI-RADS 5 lesions were detected compared to the ground truth. Targeted biopsy revealed PCa in six participants, all correctly diagnosed by both the human readers and AI. Conclusions: The results of our study show that in our AI-assisted, image-guided prostate cancer screening the software solution was able to identify highly suspicious lesions and has the potential to effectively guide the targeted-biopsy workflow.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

          Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

            Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

              The Prostate Imaging - Reporting and Data System Version 2 (PI-RADS™ v2) is the product of an international collaboration of the American College of Radiology (ACR), European Society of Uroradiology (ESUR), and AdMetech Foundation. It is designed to promote global standardization and diminish variation in the acquisition, interpretation, and reporting of prostate multiparametric magnetic resonance imaging (mpMRI) examination, and it is based on the best available evidence and expert consensus opinion. It establishes minimum acceptable technical parameters for prostate mpMRI, simplifies and standardizes terminology and content of reports, and provides assessment categories that summarize levels of suspicion or risk of clinically significant prostate cancer that can be used to assist selection of patients for biopsies and management. It is intended to be used in routine clinical practice and also to facilitate data collection and outcome monitoring for research.
                Bookmark

                Author and article information

                Journal
                Diagnostics (Basel)
                Diagnostics (Basel)
                diagnostics
                Diagnostics
                MDPI
                2075-4418
                14 November 2020
                November 2020
                : 10
                : 11
                : 951
                Affiliations
                [1 ]Department of Radiology, University Hospital of Basel, 4051 Basel, Basel-Stadt, Switzerland; daniel.boll@ 123456usb.ch
                [2 ]Siemens Healthineers, Medical Imaging Technologies Princeton, Princeton, NJ 08540, USA; bin.lou@ 123456siemens-healthineers.com (B.L.); darrylbobo@ 123456gmail.com (B.S.); ali.kamen@ 123456siemens-healthineers.com (A.K.); dorin.comaniciu@ 123456siemens-healthineers.com (D.C.)
                [3 ]Department of Urology, University Hospital of Basel, 4051 Basel, Basel-Stadt, Switzerland; christian.wetterauer@ 123456usb.ch (C.W.); MarcOlivier.Matthias@ 123456usb.ch (M.O.M.); Helge.Seifert@ 123456usb.ch (H.-H.S.); Cyrill.Rentsch@ 123456usb.ch (C.A.R.)
                Author notes
                [* ]Correspondence: davidjean.winkel@ 123456usb.ch ; Tel.: +41-61-328-65-22; Fax: +41-61-265-43-54
                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0001-7051-8022
                https://orcid.org/0000-0002-4687-8519
                https://orcid.org/0000-0002-8085-6006
                Article
                diagnostics-10-00951
                10.3390/diagnostics10110951
                7697194
                33202680
                7aec061b-f798-451a-a57c-5a39c3a8d350
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 07 September 2020
                : 11 November 2020
                Categories
                Article

                prostatic neoplasms,early detection of cancer,magnetic resonance imaging,deep learning

                Comments

                Comment on this article